Spirox Inc., a Menlo Park, CA-based medical device company, closed an $18.5m Series B round of financing.
The round was led by Venrock and Aisling Capital with participation from existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment. In conjunction with the funding, Venrock Partner Camille Samuels and Aisling Partner Aftab Kherani will join the Spirox Board of Directors along with Stacy Enxing Seng, previously President of Vascular Therapies at Covidien.
The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization.
Led by CEO Duke Rohlen, Spirox is developing a novel, minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plastic surgeons to treat patients with nasal obstruction.